Alpha-Emitting Radioantibody Lowers PSA in CRPC

Written by The Life Science Feed Editorial Team · Published 28 June 2026 · Edited by Mara Voss

> Managing castration-resistant prostate cancer (CRPC) remains a clinical challenge, particularly in patients who have progressed through standard androgen receptor pathway inhibitors and chemotherapy. The emergence of targeted radioligand therapies offers a new therapeutic avenue.1 An investigational alpha-emitting radioantibody has shown a notable reduction in prostate-specific antigen (PSA) levels in this patient population, indicating potential clinical benefit.

KEY TAKEAWAYS

- The Pivot: Alpha-emitting radioantibodies represent a novel approach for CRPC, distinct from beta-emitters, by delivering high linear energy transfer over short ranges.
- The Data: A significant proportion of patients achieved a PSA decline of e50%, with some experiencing complete PSA normalisation.
- The Action: Clinicians should monitor ongoing trials of alpha-emitting radioantibodies for CRPC, as these agents may offer a new treatment option for patients with limited alternatives.

Castration-resistant prostate cancer (CRPC) is defined by disease progression despite castrate levels of testosterone, representing a critical stage in the natural history of prostate cancer. Patients with CRPC often develop resistance to conventional androgen deprivation therapy (ADT) and subsequent androgen receptor pathway inhibitors (ARPIs) such as enzalutamide and abiraterone. Chemotherapy, typically with docetaxel or cabazitaxel, is also employed, but treatment options become increasingly limited for patients progressing through these lines of therapy. The clinical dilemma lies in identifying effective, well-tolerated treatments that can extend survival and maintain quality of life in a population with a high unmet medical need. The development of radioligand therapies, particularly those utilising alpha-emitting isotopes, offers a distinct mechanism of action compared to traditional systemic therapies, targeting cancer cells directly while sparing surrounding healthy tissue due to the short path length of alpha particles. This precision is particularly relevant in metastatic disease, where widespread but microscopic deposits may be present. The efficacy of these agents is often assessed through biochemical responses, such as prostate-specific antigen (PSA) decline, and radiological responses, alongside overall survival and progression-free survival endpoints. However, early indicators like PSA response can provide valuable insights into the potential clinical activity of a new agent. The current landscape of CRPC treatment necessitates continuous innovation to improve patient outcomes, especially for those with advanced, heavily pre-treated disease. The introduction of novel agents that can induce significant PSA reductions is a promising development, warranting close examination of their safety and efficacy profiles in rigorous clinical trials. The unique properties of alpha emitters, delivering high energy over a very short range, theoretically offer a more potent cytotoxic effect on targeted cells with reduced systemic toxicity compared to beta emitters, which have a longer path length and

lower linear energy transfer. This distinction is critical in oncology, where the therapeutic index is often narrow. The objective of these novel therapies is to achieve sustained disease control, alleviate symptoms, and ultimately prolong life, while minimising treatment-related adverse events. The evaluation of these therapies involves a comprehensive assessment of their pharmacokinetics, pharmacodynamics, and clinical outcomes. The ability to induce a substantial PSA decline is often an early indicator of anti-tumour activity, which can translate into more durable clinical benefits. Therefore, understanding the magnitude and duration of PSA responses is essential for evaluating the potential role of these investigational agents in the CRPC treatment algorithm.

The investigational alpha-emitting radioantibody

An investigational alpha-emitting radioantibody was evaluated in a cohort of patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on prior standard therapies. The study population comprised patients with documented CRPC, defined by rising PSA levels or radiological progression despite castrate testosterone levels. Patients had received prior treatment with at least one androgen receptor pathway inhibitor (ARPI) and, in many cases, prior taxane-based chemotherapy. The primary objective of the study was to assess the safety and tolerability of the radioantibody, with secondary objectives including preliminary evaluation of anti-tumour activity, as measured by PSA response and radiological response. The radioantibody was designed to target a specific antigen overexpressed on prostate cancer cells, delivering alpha radiation directly to these cells. Alpha particles, characterised by their high linear energy transfer (LET) and short path length (typically 50-100 micrometres), induce dense ionisation events, leading to double-strand DNA breaks that are difficult for cancer cells to repair. This mechanism is distinct from beta-emitting radioisotopes, which have lower LET and longer path lengths, resulting in more diffuse energy deposition. The study employed a dose-escalation design to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by an expansion cohort to further characterise the safety and efficacy profile. Patients received intravenous infusions of the radioantibody at predetermined intervals. Serial measurements of PSA were performed, along with regular monitoring of haematological parameters, renal function, hepatic function, and other safety markers. Radiological assessments, typically computed tomography (CT) and bone scans, were conducted at baseline and at scheduled intervals to evaluate objective tumour response. The inclusion criteria ensured a patient population representative of advanced CRPC, often with extensive metastatic burden, providing a real-world context for the evaluation of this novel therapeutic agent. Exclusion criteria typically included significant comorbidities that would preclude safe administration of the radioantibody or confound assessment of treatment-related adverse events. The study design aimed to provide a comprehensive understanding of the radioantibody's profile, from its pharmacokinetic behaviour to its clinical impact on disease markers and patient outcomes. The rigorous monitoring schedule was crucial for identifying any dose-limiting toxicities and for establishing a safe and effective dosing regimen. The preliminary data on PSA response served as an important early indicator of the agent's anti-tumour potential, guiding further development and larger-scale clinical trials. The selection of an alpha emitter was predicated on the hypothesis that its high cytotoxic potency and localised energy deposition could overcome resistance mechanisms encountered with other therapies, particularly in a disease known for its heterogeneity and propensity for widespread metastasis.

The preliminary analysis of the investigational alpha-emitting radioantibody demonstrated a significant biochemical response in patients with mCRPC. A substantial proportion of patients achieved a prostate-specific antigen (PSA) decline of ≥50% from baseline. Specifically, 35% of patients (N=40) in the dose-expansion cohort experienced a PSA reduction

of ≥50%. Furthermore, 15% of patients (N=40) achieved a PSA decline of ≥90%, indicating a profound anti-tumour effect in a subset of the treated population. Notably, 5% of patients (N=40) achieved PSA normalisation, defined as a PSA level below the lower limit of detection or within the normal reference range. The median time to PSA response was 8 weeks, with responses observed as early as 4 weeks post-initial dose. The duration of PSA response varied, with some patients maintaining a significant decline for several months. The safety profile indicated that the radioantibody was generally well-tolerated. The most frequently reported adverse events (AEs) were haematological, consistent with the known myelosuppressive potential of radiopharmaceuticals. Grade 3 or 4 haematological AEs included anaemia (18%), thrombocytopenia (12%), and neutropenia (8%). These events were typically transient and manageable with supportive care, such as transfusions or growth factor administration, and did not lead to treatment discontinuation in the majority of cases. Non-haematological AEs were generally mild to moderate in severity and included fatigue (25%), nausea (15%), and dry mouth (10%). No unexpected safety signals were identified, and the overall safety profile was considered acceptable for an agent in this patient population. The observed PSA responses correlated with preliminary radiological responses in a subset of patients, where reductions in tumour size or stabilisation of metastatic lesions were noted. However, the full extent of radiological response and its correlation with PSA decline requires further investigation in larger cohorts. The data suggest that the alpha-emitting radioantibody possesses significant anti-tumour activity in heavily pre-treated mCRPC patients, offering a new therapeutic modality. The high rate of PSA decline, particularly the proportion achieving ≥90% reduction and normalisation, is a compelling indicator of clinical benefit. These findings support further clinical development of this agent, including randomised controlled trials to compare its efficacy and safety against existing standard-of-care treatments. The management of haematological toxicities will be a key consideration in optimising the dosing regimen and patient selection for future studies. The short path length and high LET of alpha particles are hypothesised to contribute to the observed efficacy, by delivering potent cytotoxic doses directly to cancer cells while limiting damage to surrounding healthy tissues, thereby potentially improving the therapeutic index. The consistent and rapid PSA responses observed in a significant proportion of patients underscore the potential of this targeted alpha therapy approach in a disease setting where effective treatment options are urgently needed. The ongoing evaluation of this radioantibody will focus on confirming these preliminary efficacy signals, further characterising the long-term safety profile, and identifying biomarkers that predict response to treatment. The potential for this agent to induce deep and durable responses in a challenging patient population highlights its promise as a future therapeutic option for mCRPC.

Despite the promising preliminary results, several limitations warrant consideration. The study was a single-arm, dose-escalation and expansion trial, which inherently limits the ability to draw definitive conclusions regarding comparative efficacy against established therapies. The sample size in the expansion cohort was relatively small (N=40), which may not fully capture the spectrum of efficacy and safety events that would be observed in a larger, more diverse patient population. The follow-up duration was also limited, preventing a comprehensive assessment of long-term outcomes such as overall survival and progression-free survival. While PSA response is a valuable surrogate marker, it does not always directly translate into improved survival, and definitive clinical benefit must be confirmed in larger, randomised trials with survival endpoints. Furthermore, the study did not include a direct comparison with beta-emitting radiopharmaceuticals, making it difficult to ascertain the specific advantages of an alpha emitter in this context. The patient population was heavily pre-treated, which may influence the observed response rates and toxicity profiles, as

these patients often have compromised bone marrow reserve. The generalisability of these findings to broader CRPC populations, including those earlier in their disease course, remains to be established. Future research should focus on conducting larger, randomised controlled trials to confirm the efficacy and safety of this alpha-emitting radioantibody. These trials should include comparator arms, such as standard-of-care ARPIs or chemotherapy, to provide a clear understanding of its relative benefit. Investigations into optimal dosing regimens, scheduling, and potential combination therapies are also warranted. Biomarker identification, including specific antigen expression levels and genetic markers, could help in patient selection to maximise therapeutic benefit and minimise toxicity. Long-term follow-up data are essential to assess the durability of responses and the impact on overall survival and quality of life. Further studies should also explore the utility of this agent in earlier lines of therapy for CRPC, or in specific subgroups of patients, such as those with visceral metastases or neuroendocrine differentiation. The potential for cumulative myelosuppression with repeated doses or in combination with other myelosuppressive agents will require careful monitoring. The development of predictive biomarkers for both efficacy and toxicity will be crucial for optimising patient selection and individualising treatment strategies. Understanding the mechanisms of resistance to this radioantibody will also be important for designing future therapeutic approaches. The integration of advanced imaging techniques, such as PSMA PET scans, could further refine patient selection and monitor treatment response more precisely. The ultimate goal is to establish the role of this alpha-emitting radioantibody in the evolving treatment landscape of CRPC, providing a new, effective, and well-tolerated option for patients who have exhausted current standards of care.

CLINICAL IMPLICATIONS

The preliminary data on this alpha-emitting radioantibody for CRPC are certainly intriguing, particularly the rates of PSA decline observed in a heavily pre-treated population. For clinicians managing advanced prostate cancer, any agent demonstrating deep biochemical responses in patients who have exhausted standard ARPIs and chemotherapy is worth noting. The mechanism of action, leveraging high-LET alpha particles, offers a distinct advantage over beta-emitters, theoretically providing more potent cytotoxicity with a more localised effect. This could translate into a better therapeutic index, a critical consideration when dealing with systemic radiopharmaceuticals and their inherent myelosuppressive risks. However, the haematological toxicities, though manageable, underscore the need for careful patient selection and vigilant monitoring, particularly in a population often burdened by prior myelosuppressive treatments.

From a patient perspective, the prospect of a new treatment option that can induce significant PSA reductions, even normalisation in some cases, offers considerable hope. For those facing limited therapeutic avenues, the potential for disease control and symptom palliation is paramount. The relatively rapid onset of PSA response, within weeks, could provide early reassurance of treatment efficacy. However, patients must be counselled on the potential for haematological adverse events and the need for frequent monitoring. The current data, while promising, are from early-phase trials, and the long-term impact on overall survival and quality of life remains to be fully elucidated. The industry, particularly companies developing radioligand therapies, will be closely watching these developments. The success of agents like lutetium-177 PSMA-617 has paved the way for further investment in targeted radiopharmaceuticals. An alpha-emitter with a favourable safety and efficacy profile could carve out a significant niche, especially if it demonstrates superiority or non-inferiority to existing options in specific patient subgroups. The manufacturing and logistical challenges associated

with alpha-emitters are considerable, but the clinical demand for effective CRPC treatments will likely drive continued innovation and investment in this space.

The next steps are clear: larger, randomised controlled trials are essential to confirm these early signals and establish the definitive role of this alpha-emitting radioantibody in the CRPC treatment algorithm. These trials must compare it against current standards of care, such as cabazitaxel or subsequent ARPIs, and ideally include survival endpoints. Furthermore, identifying predictive biomarkers will be crucial for optimising patient selection and ensuring that the right patients receive the right therapy. The potential for this class of agents to address unmet needs in CRPC is substantial, but the journey from promising early data to established clinical practice requires rigorous validation. Clinicians should remain cautiously optimistic, awaiting the robust evidence from pivotal trials that will ultimately define its place in our armamentarium against advanced prostate cancer.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-Targeted ±Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941-1944. doi:10.2967/jnumed.116.178673
2. 2. Sathekge M, Bruchertseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129-138. doi:10.1007/s00259-018-4167-0
3. 3. Sathekge M, Bruchertseifer F, Vorster M, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):212-223. doi:10.1016/S1470-2045(23)00638-1
4. 4. Parida GK, Panda RA, Bishnoi K, Agrawal K. Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis. Med Princ Pract. 2023;32(3):178-191. doi:10.1159/000531246
5. 5. Hammer S, Hagemann UB, Zitzmann-Kolbe S, et al. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res. 2020;26(8):1985-1996. doi:10.1158/1078-0432.CCR-19-3016

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.